Last reviewed · How we verify
NCT07265037
Integrated TCM - Western Medicine Strategy for Long - Distance Diabetes Management
NA trial testing Integrated TCM-Western Medicine Intelligent Diabetes Management Platform in Diabetes Mellitus, Type 2 in 10,000 participants. Currently enrolling.
28 February 2026
Quick facts
| Lead sponsor | Shanxi Bethune Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 10,000 |
| Start date | 1 November 2025 |
| Primary completion | 28 February 2026 |
| Estimated completion | 31 May 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Integrated TCM-Western Medicine Intelligent Diabetes Management Platform
Conditions studied
- Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →
- Integrated Traditional Chinese Medicine and Western Medicine — all drugs for Integrated Traditional Chinese Medicine and Western Medicine →
- Telemedicine — all drugs for Telemedicine →
- Chronic Disease Management — all drugs for Chronic Disease Management →
Sponsor
Shanxi Bethune Hospital
Who can join
18 and older, any sex, with Diabetes Mellitus, Type 2 or Integrated Traditional Chinese Medicine and Western Medicine. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The management of diabetes is of great value in reducing the risk of complications and alleviating the socioeconomic burden. Currently, the diabetes management models in China have not effectively integrated the advantages of traditional Chinese medicine (TCM) and Western medicine. They also fail to achieve intelligent and automated management, resulting in high management costs and low efficiency. Therefore, it is extremely urgent to explore a new, efficient, convenient, low - cost, and personalized long - distance, full - course, intelligent management model for diabetes that integrates TCM and Western medicine both online and offline. Based on this, our research group plans to rely on the pre - designed and developed Idata database. We will deeply integrate the diagnostic and treatment advantages of TCM constitution differentiation and Western medical examinations and laboratory tests, construct an automated follow - up path, and build an integrated online diabetes management platform for Internet hospitals, which consists of "intelligent hardware + APP + cloud services + a back - end think - tank of TCM and Western medicine experts + a back - end professional management and care team". This initiative aims to blaze a new trail in the field of long - distance, full - course, and personalized management of diabetes through the synergy of TCM and Western medicine for Chinese diabetes patients. We expect to significantly reduce the incidence of diabetes complications, remarkably improve the overall health status and quality of life of patients, and bring unprecedented positive impacts on the well - being of diabetes patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07265037
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetes Mellitus, Type 2
Currently open trials in the same condition.
- NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
- NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
- NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
- NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
- NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting
Other Shanxi Bethune Hospital trials
Trials by the same sponsor.
- NCT07371533 — Clinical Study of Recombinant Anti-CD19m-CD3 Antibody Injection (A-319) · NA · not yet recruiting
- NCT07514052 — Predicting Response to Selinexor-Based Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Prospective Study · recruiting
- NCT07239375 — Intraosseous Infusion in Hematologic Critical Patients · recruiting
- NCT07497165 — Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma · recruiting
- NCT07204522 — Efficacy of Empirical Anti-Infective Therapy in Neutropenic Febrile Patients. · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07265037 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanxi Bethune Hospital
- Last refreshed: 4 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07265037.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing